EU/3/17/1917

About

On 16 October 2017, orphan designation (EU/3/17/1917) was granted by the European Commission to Sagetis Biotech, S.L., Spain, for adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters (also known as SAG-101), for the treatment of pancreatic cancer.

Key facts

Active substance
Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters
Disease / condition
Treatment of pancreatic cancer
Date of first decision
16/10/2017
Outcome
Positive
EU designation number
EU/3/17/1917

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Sagetis Biotech, S.L.
Via Augusta, 394
08017 Barcelona
Spain
Tel. +34 933097169
E-mail: xrivero@sagetis-biotech.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating